Nasus Pharma is trading 6.76% down at $3.52, with no new company-specific announcement dated September 3, 2026 identified.
- The stock is weaker after closing at $3.77 on September 2, 2026.
- Healthcare and major U.S. indices are higher, so neither sector nor broad-market direction clearly explains the decline.
- Wider first-half losses and increased clinical-development spending are older catalysts.